A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial
Authors:
- Adrian BibbyABAdrian Bibby
- Richard FosterRFRichard Foster
- 22 October 2010
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 49 (11) , 1328-1333
Abstract
The calcipotriene/betamethasone dipropionate two‐compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non‐Hispanic. The aim of this study was to evaluate the efficacy and safety of the two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients. A total of 99 Hispanic/Latino and 78 Black/African American patients were randomized double‐blind in a 3 : 1 ratio to 8 weeks of once daily treatment of scalp psoriasis with either the two‐compound scalp formulation (n = 135) or its vehicle (n = 42). In the two‐compound group, 71.9% of patients had cleared or minimal disease at week 8 by the investigator’s global assessment compared to 40.5% in the vehicle group (odds ratio 3.30; 95% CI 1.62–6.72; P < 0.001). For the five secondary efficacy response criteria, three (total sign score, thickness of scalp psoriasis, patient’s global assessment) showed that two‐compound scalp formulation was statistically significantly more effective than its vehicle, and the other two (redness and scaliness of scalp psoriasis) approached statistical significance in favor of the two‐compound scalp formulation. There was no statistically significant difference (P = 1.00) between the percentage of patients with adverse reactions in the two‐compound group (7.0%) and the vehicle group (7.9%). The two‐compound scalp formulation is safe and effective in the treatment of scalp psoriasis over 8 weeks in Hispanic/Latino and Black/African American patients.Keywords
This publication has 8 references indexed in Scilit:
- A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trialBritish Journal of Dermatology, 2009
- A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trialJournal of the American Academy of Dermatology, 2008
- Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasisJournal of the American Academy of Dermatology, 2003
- A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgarisDermatology, 2002
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Treatment of PsoriasisNew England Journal of Medicine, 1995
- The Natural History of Psoriasis in 5,600 PatientsDermatology, 1974
- PsoriasisArchives of Dermatology, 1968